The Resistant Pseudomonas aeruginosa Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Resistant Pseudomonas aeruginosa Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Resistant Pseudomonas aeruginosa Infections by 15 companies/universities/institutes. The top development phase for Resistant Pseudomonas aeruginosa Infections is preclinical with seven drugs in that stage. The Resistant Pseudomonas aeruginosa Infections pipeline has 11 drugs in development by companies and four by universities/ institutes. Some of the companies in the Resistant Pseudomonas aeruginosa Infections pipeline products market are: VenatoRx Pharmaceuticals, Myers Research Institute and Southern Research Institute.
The key targets in the Resistant Pseudomonas aeruginosa Infections pipeline products market include Penicillin Binding Protein, PcrV Protein, and UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase.
The key mechanisms of action in the Resistant Pseudomonas aeruginosa Infections pipeline product include Penicillin Binding Protein Inhibitor with two drugs in Phase III. The Resistant Pseudomonas aeruginosa Infections pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Resistant Pseudomonas aeruginosa Infections pipeline products market including Small Molecule, and Biologic.
Resistant Pseudomonas aeruginosa Infections overview
Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers, and headache. Risk factors include age and weakened immune system.
For a complete picture of Resistant Pseudomonas aeruginosa Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
